{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:03:11Z","timestamp":1767135791990,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd008516","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000}}],"reference-count":67,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008516.pub2","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T18:37:25Z","timestamp":1346783845000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients"],"prefix":"10.1002","volume":"2012","author":[{"given":"Lior H","family":"Katz","sequence":"first","affiliation":[{"name":"MD Anderdson Cancer Center; Hepatology and Nutrition Department; 1515 Holcombe st. Houston Texas USA 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Oncology; Petah Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tur-Kaspa","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine D; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"key":"10.1002\/14651858.CD008516.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1086\u201397","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008516.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep.23816","article-title":"Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with HCV genotype 1 and slow virologic response","volume":"52","author":"Buti","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD008516.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2011.04911.x","article-title":"Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3","volume":"35","author":"Lee","year":"2012","journal-title":"Alimentary Pharmacolology and Therapuetics"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0004|cit4","unstructured":"Liu C-H Liang C-C Liu C-J Lin C-L Yang S-S Hsu S-J Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response Hepatology International 2011"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.22061","article-title":"Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial","volume":"47","author":"Mangia","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.21919","article-title":"Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1\u2013infected slow responders","volume":"46","author":"Pearlman","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"451\u201360","DOI":"10.1053\/j.gastro.2006.05.016","article-title":"Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment","volume":"131","author":"S\u00e1nchez-Tapias","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.gastro.2009.10.058","article-title":"Peginterferon alfa-2a\/ribavirin for 48 or 72 weeks in hepatitis C types 1and 4 patients with slow virologic response","volume":"138","author":"Ferenci","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ajg.2008.60","article-title":"A randomized study of extended treatment with peginterferon \u03b1-2b plus ribavirin based on time to HCV RNA negative \u2013 status in patients with genotype 1b chronic hepatitis C","volume":"104","author":"Ide","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2957\/kanzo.51.48","article-title":"The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12","volume":"51","author":"Miyase","year":"2010","journal-title":"Acta Hepatologica Japonica"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"343\u201351","DOI":"10.1111\/j.1365-2036.2009.04048.x","article-title":"Clinical trial: extended treatment duration of peginterferon alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders","volume":"30","author":"Nagaki","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(10)60056-6","article-title":"Completely individualized treatment durations (24, 30, 36, 42, 48, 60 or 72 weeks) with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients (INDIV-2 study)","volume":"52","author":"Sarrazin","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD008516.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/00042737-200411000-00022","article-title":"Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis","volume":"16","author":"Abergel","year":"2004","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD008516.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.5812\/kowsar.1735143X.2187","article-title":"Optimal duration of treatment for HCV genotype 1 infection in slow responders: A meta-analysis","volume":"11","author":"Alavian","year":"2011","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/hep.22991","article-title":"Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients","volume":"50","author":"Berg","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008516.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008516.pub2-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/jhep.2003.50107","article-title":"Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1chronic hepatitis C late responders: a report of 9 cases","volume":"37","author":"Buti","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0021|cit21","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis http:\/\/ctu.dk\/tsa\/ (accessed January 2011)"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD008516.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/sim.4780060706","article-title":"Practical aspects in data monitoring: a brief review","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008516.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hep.24480","article-title":"Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future","volume":"54","author":"Martino","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon","volume":"53","author":"Bisceglie","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1086\/382279","article-title":"A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus","volume":"189","author":"Drusano","year":"2004","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008516.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.cgh.2010.06.019","article-title":"Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection","volume":"8","author":"Farnik","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Pefintereron alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008516.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jclinepi.2004.09.013","article-title":"Uncertainty method improved on best-worst case analysis in a binary meta-analysis","volume":"58","author":"Gamble","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD008516.pub2-BIB0033|cit33","first-page":"216","article-title":"Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review","volume":"69","author":"Gevers","year":"2011","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0035|cit35","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2012, Issue 5. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008516.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0039|cit39","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Colloboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0040|cit40","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"5","key":"10.1002\/14651858.CD008516.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon-2a (40 kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2036.2004.02208.x","article-title":"Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4","volume":"20","author":"Khuroo","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1680\u20136","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD008516.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatits C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MOG.0b013e3283383c8f","article-title":"New therapies in the management of hepatitis C virus","volume":"26","author":"Michaels","year":"2010","journal-title":"Current Opinions in Gastroenterology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Parikh M Singh A Sood G Extended treatment duration for treatment naive chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin Journal of Viral Hepatitis 2010 e99 e103 10.1111\/j.1365-2893.2010.01374.x","DOI":"10.1111\/j.1365-2893.2010.01374.x"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter study group","volume":"332","author":"Poynard","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0055|cit55","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD008516.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008516.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0168-8278(09)60614-0","article-title":"Week 8 HCV-RNA is the optimal predictor of relapse in non-RVR patients with genotype 1\/4 randomised to 48 or 72 weeks PEG-IFN alfa-2A plus RBV","volume":"50","author":"Scherzer","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD008516.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0059|cit59","first-page":"41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Theodore","year":"2006","journal-title":"International Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"Thomas","year":"2005","journal-title":"Clinical Liver Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008516.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0062|cit62","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0063|cit63","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual forTrial Sequential Analysis (TSA) http:\/\/ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1440-1746.2009.05814.x","article-title":"Prevention of hepatocellular carcinoma complicating chronic hepatitis C","volume":"24","author":"Ueno","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD008516.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008516.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in a random-effects meta-analysis","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"7644","key":"10.1002\/14651858.CD008516.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008516.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:17:36Z","timestamp":1730863056000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008516.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008516.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}